Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 2

Original source

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 2Motor Neurone Disease Association (UK) · 29 November 2023 (opens in a new tab)

Related topics

The International Symposium on ALS/MND will include three joint sessions on amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Planned talks will cover early disease stages, cognitive and behavioural symptoms, TDP-43 protein clumps, disease models and genetic therapies. The sessions are intended to encourage collaboration between ALS and FTD researchers.

Why this matters

The programme may help researchers compare the two conditions, improve terminology and identify possible treatment targets. It does not change treatment for people with ALS or FTD because the source describes planned presentations and research areas, not clinical results.

Limitations and context

This is an organisational preview published by the Motor Neurone Disease Association before the symposium. It describes planned talks and research topics, rather than reporting peer-reviewed findings or results from a completed study. Any proposed biomarkers, subtypes or treatments would still need validation in research and clinical trials.

Summarised by Compass 9 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?